Cardinal Health executives used the company’s fiscal Q2 earnings call to detail how investments are affecting revenue, reshaping operations across its pharmaceutical, specialty and logistics businesses.
The Dublin, Ohio-based health care distributor focuses on its investments in ecommerce, patient-support digitization, distribution center automation and data tools.
Cardinal Health posted Q2 revenue of $65.6 billion. That a 19% increase from $55.3 billion a year earlier. Net income attributable to Cardinal Health rose to $467 million. That compares with $400 million in the same quarter last year, a 17% gain.
For the first six months of fiscal 2026, revenue reached $129.6 billion, up from $107.5 billion a year earlier, a 21% increase. Year-to-date net income climbed to $917 million from $816 million, up 12%.
Chief financial officer Aaron Alt tied those upgrades directly to distribution performance, saying operations teams are “leveraging our investments in technology infrastructure, such as the Ventus HQ ecommerce platform to drive customer efficiency and streamline our operations, which directly supports our margin profile.”
CEO Jason Hollar said technology and network investments have also translated into measurable service gains. He told analysts those investments “have contributed to improved service levels, including a 10% improvement over the past two years, setting a new benchmark for product availability.”
How Cardinal Health grew revenue in Q2
Hollar pointed to recent business wins in Cardinal’s biopharma services unit, Sonexus, as evidence that digitization efforts are resonating with drug manufacturers.
He said “a number of key manufacturer partners have recently selected our Sonexus access and patient support business to support their hub programs totaling over 1 million new patients served.” He added that those wins “were enabled by our significant investments to digitize the patient support journey.”
Later in the call, he described what differentiates the platform. “The digitization that we did with our tool, our platform,” Hollar said, allows manufacturers — once they bring one product onto the system — to replicate it “quite seamlessly” across other products.
Alt reiterated the company’s longer-term financial goal for the business. He said Cardinal Health has “committed to getting the biopharma services part of the portfolio to $1 billion revenue by 2028.” He added that biopharma services are “growing within the year, up 30%, half of it from Sonexus.”
Hollar also detailed technology work underway in Cardinal’s at-home solutions business, which serves patients with chronic conditions through direct-to-home distribution.
“We’re very much focused on the distribution network, continuing to build out the automation and the technology there,” he said. “We’ve completed 3 of the 11 DCs. We have another three to go for the next three years.”
In Cardinal’s OptiFreight Logistics unit, Hollar highlighted continued investment in a proprietary platform it designed to improve shipment visibility and cost management for health care customers.
“With ongoing investments in our proprietary technology-driven platform, Total View Insights, we see long-term potential to deliver cost savings, transparency and operational efficiency for our customers,” he said. He added that Cardinal is also developing “new customer-centric technology to expand our presence in the pharmacy space.”
What is Cardinal Health using AI for?
While executives did not announce specific AI products, Hollar explicitly referred to AI as part of broader efficiency efforts across the company.
“We’re always looking for productivity, efficiency, using technology, AI and just elbow grease to go after and to take cost out,” he said. “But then we’re always also looking for — well, where can we invest that with a great return … It’s not today’s problems, but we’re spending on tomorrow’s opportunities.”
Alt echoed that theme, saying leadership is focused on investing for the future while “relentlessly” optimizing the company’s cost structure.
Hollar described technology as a core element of Cardinal’s specialty growth strategy, linking distribution, physician practice platforms and biopharma services into what he called a “flywheel effect.”
“These capabilities, both upstream with the manufacturers and downstream with our customers and ultimately patients, all work together,” he said, adding that the approach is driving “across the board performance improvements.”
He reiterated on the Q2 call that Cardinal Health expects specialty revenue to surpass $50 billion in fiscal 2026, a target he said reflects the scale of the company’s investments and momentum in specialty distribution, MSO platforms and biopharma services.
Sign up
Sign up for a complimentary subscription to Digital Commerce 360 B2B News. It covers technology and business trends in the growing B2B ecommerce industry. Contact Mark Brohan, senior vice president of B2B and Market Research, at mark@digitalcommerce360.com. Follow him on Twitter @markbrohan. Follow us on LinkedIn, X (formerly Twitter), Facebook and YouTube.